| 1 |
tyrosine kinase inhibitors
(5667 times)
|
Neoplasms
(2668 times)
|
EGFR (1752 times)
NSCLC (1589 times)
CML (1051 times)
|
1997 Inhibitors of tyrosine kinase.
|
| 2 |
TK inhibitors
(22 times)
|
Neoplasms
(7 times)
|
TK (14 times)
EGFR (8 times)
TKs (7 times)
|
2003 The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer.
|
| 3 |
tyrosine kinases
(10 times)
|
Neoplasms
(4 times)
|
EGFR (2 times)
HCC (2 times)
mAbs (2 times)
|
2009 Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
|
| 4 |
tyrosine kinase receptor inhibitors
(6 times)
|
Drug Therapy
(1 time)
|
EGFR (2 times)
NSCLC (2 times)
CPIs (1 time)
|
2013 Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma.
|
| 5 |
tyrosine kinase activity
(3 times)
|
Chemistry
(1 time)
|
EGFR (1 time)
mAbs (1 time)
MBC (1 time)
|
2011 The role of antiangiogenetic agents in the treatment of breast cancer.
|
| 6 |
tyrosine kinase receptors
(3 times)
|
Chemistry, Pharmaceutical
(1 time)
|
MTC (1 time)
SAR (1 time)
|
2009 Multitarget drugs: the present and the future of cancer therapy.
|
| 7 |
anti-tyrosine kinases
(2 times)
|
Neoplasms
(2 times)
|
EGFR (1 time)
NSCLC (1 time)
PFS (1 time)
|
2017 Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
|
| 8 |
topological Kondo insulators
(2 times)
|
Biomedical Research
(1 time)
|
KIs (1 time)
MR (1 time)
SS (1 time)
|
2016 Surface Kondo effect and non-trivial metallic state of the Kondo insulator YbB12.
|
| 9 |
Tyr-kinase inhibitors
(2 times)
|
Cell Biology
(2 times)
|
FAs (1 time)
FASN (1 time)
mTOR (1 time)
|
2008 Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.
|
| 10 |
tyrosine kinase activity inhibitors
(2 times)
|
Chemistry
(1 time)
|
ABC (1 time)
CML (1 time)
EM (1 time)
|
2015 Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia.
|
| 11 |
tyrosine kinase domain
(2 times)
|
Biotechnology
(1 time)
|
CCK-8 (1 time)
mAbs (1 time)
NSCLC (1 time)
|
2008 ErbB antagonists patenting: "playing chess with cancer".
|
| 12 |
EGFR-TK inhibitors
(1 time)
|
Toxicology
(1 time)
|
mAbs (1 time)
|
2017 Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma.
|
| 13 |
Multi-kinase inhibitors
(1 time)
|
Liver Neoplasms
(1 time)
|
anti-PD-1 (1 time)
HCC (1 time)
|
2021 Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options.
|
| 14 |
receptor kinase inhibitors
(1 time)
|
Neoplasms
(1 time)
|
ccRCC (1 time)
TKI (1 time)
|
2015 Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience.
|
| 15 |
targeted by RTK inhibitors
(1 time)
|
Neoplasms
(1 time)
|
RTK (1 time)
|
2015 The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.
|
| 16 |
targets for specific kinase inhibitors
(1 time)
|
Veterinary Medicine
(1 time)
|
OSAs (1 time)
PDGFR (1 time)
|
2012 PDGFs and PDGFRs in canine osteosarcoma: new targets for innovative therapeutic strategies in comparative oncology.
|
| 17 |
Third-generation EGFRtyrosine kinase inhibitors
(1 time)
|
Neoplasms
(1 time)
|
---
|
2021 MARIPOSA: phase 3 study of first-line amivantamab+lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
|
| 18 |
TK domain inhibitors
(1 time)
|
Neoplasms
(1 time)
|
---
|
2012 Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy.
|
| 19 |
treated with kinase inhibitors
(1 time)
|
Hematology
(1 time)
|
CML (1 time)
|
2011 Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia.
|
| 20 |
tyrosine kinase enzymatic activity
(1 time)
|
Thoracic Diseases
(1 time)
|
EGFR (1 time)
mAb (1 time)
NSCLC (1 time)
|
2012 Treatment of advanced non small cell lung cancer.
|
| 21 |
tyrosine kinase inhibitor resistance
(1 time)
|
Genomics
(1 time)
|
TNBC (1 time)
|
2021 Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
|
| 22 |
tyrosine kinase inhibitors treatments
(1 time)
|
Public Health
(1 time)
|
CML (1 time)
|
2017 Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.
|
A Search Service for Abbreviation / Long Form